|  |  |
| --- | --- |
| **Fluorescent Target Molecule (Protein) 2:** | |
| General information | |
| Name (full name and/or abbreviation) | SARS-CoV-2 (COVID-19) Nucleocapsid protein FL |
| Uniprot accession code | QHO62115.1 |
| Biochemical details | |
| Domain boundaries | 1 - 419 |
| Calculated molecular weight [kDa] | 49.4 |
| Details (SS bridges, mutations, glycosylation etc.) (if any) | Without glycosylation (E. coli expression) |
| Co-factors for binding/activity (e.g. Ca2+-dependent) | NA |
| Fusion protein with a tag? (His, Strep, etc.) | His-tag |
| Availability and stability | |
| Supplier | Acro Biosystems |
| Purity | >90% as determined by SDS-PAGE |
| Comments | |
|  | |
| Recommendations from Crelux | |
| Preferred constructs and sources:   1. Nucleocapsid FL without glycosylation (see information above):    * Acro Biosystems NUN-C51H9    * <https://www.acrobiosystems.com/P3112-SARS-CoV-2-%28COVID-19%29-Nucleocapsid-protein-His-Tag.html> 2. Nucleocapsid FL with glycosylation (alternative):    * Acro Biosystems NUN-C5227    * <https://www.acrobiosystems.com/P3152-SARS-CoV-2-%28COVID-19%29-Nucleocapsid-protein-His-Tag.html> | |

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| **Small molecule (and protein) interactions to analyze:** | | | | |
|  | Titrant | Expected Kd or IC50 (if available) | Solubility in assay buffer (if available) | Comments |
| 1 | nanobody | nM range | NA | For assay setup – provided by client |
| 2 | Unlabeled RNA | µM range | NA | For assay setup – purchased by Crelux |
| 3 |  |  |  |  |
| 4 |  |  |  |  |
| 5 |  |  |  |  |
| 6 |  |  |  |  |
| 7 |  |  |  |  |
| 8 |  |  |  |  |
| 9 |  |  |  |  |
| 10 |  |  |  |  |
| 11 |  |  |  |  |
| 12 |  |  |  |  |
| 13 |  |  |  |  |
| 14 |  |  |  |  |
| 15 |  |  |  |  |
| 16 |  |  |  |  |
| 17 |  |  |  |  |
| 18 |  |  |  |  |
| 19 |  |  |  |  |
| 20 |  |  |  |  |